touchCONGRESS HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?

In this interview, Eva Ciruelos answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Dr Eva M. Ciruelos is Medical Oncologist and Coordinator of the Multidisciplinary Breast Cancer Unit at the University Hospital 12 de Octubre in Madrid, Spain. She is current coordinator of Breast Cancer Unit at HM private hospitals in Madrid. Additionally, she has been an Associate Professor in the Department of Medicine at the Complutense University of Madrid Faculty of Medicine since 2008.

Dr Ciruelos is the Principal Investigator of several clinical trials and research projects in breast cancer and is on the Steering committee for several registration clinical trials. She is the current vice president of the Solid Tumor Intensification (SOLTI) Group and is also a member of the scientific Committee of the Breast International Group (BIG) and the St Gallen Conference Panel. Dr Ciruelos is an author and reviewer of Oncology practice guidelines with national (Spanish Society of Medical Oncology) and international impact.

She has contributed to oncology textbook chapters, and is an author or co-author of articles with a focus on breast cancer research. She also plays an active role in medical education events for breast cancer.

Dr Eva Ciruelose discloses:  Personal fees for speaker and advisory board services from Lilly and Novartis. Personal fees for speaker and advisory board services and congress assistance from Pfizer and Roche.

In this interview, George Sledge answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Prof. George W. Sledge, MD, is Professor and Chief of Medical Oncology at Stanford University Medical Center.  He specialises in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He has published over 290 scientific articles spanning both laboratory and clinical issues.

Prof. Sledge serves as Editor-in-Chief of Clinical Breast Cancer, and is a Past-President of the American Society of Clinical Oncology. He served as chair of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 – 2009, where he led the development of nationwide clinical trials. Prof. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’, and was also the recipient of the 2006 Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation’s Jill Rose Award and the 2010 William L. McGuire Award from the San Antonio Breast Cancer Symposium.

Prof. George Sledge discloses:  Consultancy role/expenses from Radius Health, Symphogen, Synaffix, Taiho pharmaceutical and Verseau therapeutics.  Board of Directors for Syndax, Tessa Therapeutics, Verseau Therapeutics Stocks: Syndax and Tessa Therapeutics Research funding from Genentech/Roche, Pfizer

In this interview, Norikazu Masuda answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Dr Norikazu Masuda became the breast oncology specialist at Sakai Municipal Hospital in 2001. Then, in 2003, he moved to Osaka National Hospital and has served as a clinical professor of the Department of Breast and Endocrine Surgery at the Graduate School of Medicine, Osaka University since 2014. His doctoral research established the clinical significance of micro-metastasis detection in axillary lymph nodes after establishing RNA extraction technology from formalin-fixed specimens.

Dr Masuda has the following board certifications: Board Certified Surgeon (2002) and Supervisor (2007) of the Japan Surgical Society, Board Certified Breast cancer specialist (2005) of the Japanese Breast Cancer Society. He serves as a councillor of the Japanese Breast Cancer Society (1998-) and councillor of the Japan Association of Breast Cancer Screening (2005-).

He is a member of numerous professional organizations such as ASCO, ESMO, the Japanese Breast Cancer Society, the Japanese Cancer Association, the Japan Society of Clinical Oncology and the Japan Surgical Society. He is one of the directors of Japanese Breast Cancer Research Group (JBCRG) and works as a principal investigator of some prospective multicenter clinical trials.

Dr Norikazu Masuda discloses:  Honoraria from AstraZeneca, Chugai, Eli-Lilly, Eisai, Pfizer and Takeda.  Board of directors for Japan Breast Cancer Research Group (JBCRG) Association.  Research funding to institution from AstraZeneca, Chugai, Daiichi Sankyo, Eli-Lilly, Eisai, Kyowa-Kirin, MSD, Novartis and Pfizer.

In this interview, Fátima Cardoso answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Dr Dr Fátima Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal. Dr Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials for which she has received grants from a variety of foundations and societies, as well as serving as the scientific director of the international research network TRANSBIG. Dr Cardoso is actively involved in numerous professional organizations such as ESMO, EORTC, ASCO, and AACR where she serves on several committees. She is also the Breast Cancer Program Coordinator of the European School of Oncology and chair of the Advanced Breast Cancer International Consensus Guidelines Conference. Dr Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She was awarded the prestigious Order of Santiago da Espada for Scientific Merit, from the President of Portugal in 2015. Dr Cardoso has authored about 300 publications and has presented her work nationally and internationally.

Dr Fátima Cardoso discloses:   Consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck Sharp & Dohme, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics and Teva.  Clinical trial funding (to the institute) from Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eisai, Fresenius GmbH, Genentech, GlaxoSmithKline, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Tesaro, Tigris, Wilex and Wyeth.

In this interview, Frédérique Penault-Llorca answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Prof. Frédérique Penault-Llorca is currently Chief Executive Officer of the Jean-Perrin Comprehensive Cancer Center, Clermont-Ferrand, France.

Frédérique Penault-Llorca became Professor and Hospital Practitioner in the Faculty of Medicine at Clermont Auvergne University and the Jean Perrin Center in 2002. In 2013, she became the General Manager of the Jean Perrin Center and a member of the UNICANCER group. During 2013 she also became Vice-President of the Oncauvergne network and in 2015, Vice-president of UNICANCER. Prof. Penault-Llorca is deputy director of UMR INSERM 1240 IMoST (Imagerie Moléculaire et Stratégies Théranostiques) and also a board member of the National Cancer Institute.

Professor Penault-Llorca’s research focuses on the characterisation and prediction of treatment response in women’s cancers, in particular triple negative or HER2-positive aggressive cancers. In addition, she has research interests in molecular theragnostic markers for lung and colon cancers. She is President of the Immuno-Oncology Group for research and development in UNICANCER and coordinates immunotherapy biomarker research with the National Cancer Institute and the French Society of Pathology in collaboration with the French Association of Quality Assurance in Pathological Anatomy and Cytology.

Prof. Prof. Frédérique Penault-Llorca discloses:  Advisory or consultancy role for AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck Sharp & Dohme GmbH and Roche.  Grants for clinical research from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck Sharp & Dohme GmbH, Novartis, Pfizer and Roche.

In this interview, Jens Huober answers the following questions:

• Additional efficacy data for CDK4/6 inhibitors were presented at SABCS 2019. In your opinion, how will these findings affect clinical practice in your region?
• Real-world evidence for CDK4/6 inhibitors has been presented at SABCS 2019. How valuable are these findings to help inform treatment decisions in your clinical practice?
• In your opinion, what are the practical challenges of managing adverse events with CDK4/6 inhibitors in the real-world clinical practice?
• In your opinion, can data from biomarker analyses studies presented at SABCS 2019 be used to guide the selection of patients for CDK4/6 inhibitors in daily practice?
• Considering the data presented at SABCS for patients with HR+/HER2- advanced breast cancer, what are the ongoing challenges you face in daily clinical practice?

Prof. Dr Jens Huober is currently the Director of the Department of Obstetrics and Gynaecology of the University of Ulm, Germany.  Previously, he was the Senior Staff member at the Breast Center at Kantonsspital St. Gallen in Switzerland, Head of the outpatient unit at the Gynaecologic Department at the University of Tuebingen and also undertook a research fellowship at the M.D. Anderson Cancer Center, Texas. Prof. Huober is board certified in Gynaecology and Obstetrics (2000), Systemic Tumour Therapy (2007) and Palliative Medicine (2010).

His clinical interests include systemic treatment of breast and gynaecological cancers, and senology. He is actively involved in cooperative research with the International Breast Cancer Study Group (IBCSG), the German Breast Group (GBG) and the Detect Study Group.

Prof. Huober undertakes clinical and translational research activities including Phase 1-3 clinical studies in breast and gynaecological cancers and evaluation of predictive factors for response to neoadjuvant treatment. He is head of the Registry Study on Biological Disease Profile and Clinical Outcome in Patients with newly diagnosed Breast or Ovarian Cancer – The BRandO Biology and Outcome (BiO)-Project.

Prof. Huober is a member of numerous professional organisations such as the German Cancer Society, the German Society of Gynaecological Oncology, the German Society of Gynaecology and Obstetrics, the German Society of Senology and ASCO.

Prof. Dr Jens Huober discloses:  Advisory boards for Abbvie, AstraZeneca, Celgene, Hexal, Lilly, MSD, Novartis, Pfizer and Roche. Honoraria from Abbvie, AstraZeneca, Celgene, Eisai, Lilly, MSD, Novartis, Pfizer and Roche. Research grants from Celgene, Hexal, Novartis. Travel expenses: Celgene, Daiichi, Novartis, Pfizer and Roche.